# Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

> **NCT02808975** · PHASE4 · COMPLETED · sponsor: **AbbVie** · enrollment: 206 (actual)

## Conditions studied

- Hidradenitis Suppurativa (HS)

## Interventions

- **DRUG:** Placebo
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT02808975
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-18
- **Primary completion:** 2019-05-16
- **Final completion:** 2019-10-16
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2020-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02808975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02808975, "Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02808975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*